Vaccine

NFID Launches New Spanish Website for Disease Prevention and Treatment

New Spanish Website Aims to Educate and Empower Patients, Caregivers, and Healthcare Professionals to Make Informed Health Decisions BETHESDA, Md.,…

1 year ago

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

1 year ago

Elicio Therapeutics Reports Inducement Grants

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company…

1 year ago

Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License

ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company…

1 year ago

SpyBiotech Appoints Keith Dewedoff as new Chief Financial Officer

OXFORD, England and CAMBRIDGE, Mass., June 18, 2024 /PRNewswire/ -- SpyBiotech, a biotechnology company with a novel vaccine platform technology…

1 year ago

Defence’s Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

1 year ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to…

1 year ago

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains…

1 year ago

Velocity Clinical Research partners with Luminis Health, moves into oncology in the U.S.

Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans DURHAM, N.C., June 12,…

1 year ago